Cargando…
Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma
Recent advances in molecular technologies enable sensitive and quantitative assessment of circulating tumor DNA, offering a noninvasive disease monitoring tool for patients with malignant disorders. Here, we demonstrated on four follicular lymphoma cases that circulating tumor DNA based EZH2 mutatio...
Autores principales: | Nagy, Ákos, Bátai, Bence, Balogh, Alexandra, Illés, Sarolta, Mikala, Gábor, Nagy, Noémi, Kiss, Laura, Kotmayer, Lili, Matolcsy, András, Alpár, Donát, Masszi, Tamás, Masszi, András, Bödör, Csaba |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397208/ https://www.ncbi.nlm.nih.gov/pubmed/32668764 http://dx.doi.org/10.3390/genes11070785 |
Ejemplares similares
-
P1245: PARALLEL TESTING OF LIQUID BIOPSY (CTDNA) AND TISSUE BIOPSY SAMPLES REVEALS A HIGHER FREQUENCY OF TARGETABLE EZH2 MUTATIONS IN FOLLICULAR LYMPHOMA
por: Bátai, Bence, et al.
Publicado: (2023) -
Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax
por: Kotmayer, Lili, et al.
Publicado: (2023) -
PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION
por: László, Tamás, et al.
Publicado: (2023) -
Liquid biopsy-based monitoring of residual disease in multiple myeloma by analysis of the rearranged immunoglobulin genes–A feasibility study
por: Marx, Anita, et al.
Publicado: (2023) -
Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
por: Szita, Virág Réka, et al.
Publicado: (2022)